Insulet (NSDQ:PODD) last week presented positive pivotal trial data for its Omnipod 5 automated insulin delivery system.
Acton, Massachusetts-based Insulet’s Omnipod 5 — which it touts as the world’s first tubeless wearable system for continuously adapting insulin delivery based on glucose levels and trends — significantly improved time in range and reduced HbA1c in the trial.
Get the full story at our sister site, Drug Delivery Business News.